Table 1

Demographic characteristics of patients with AIIRD and controls

Age, median (range)Female
n (%)
Disease duration, years*Influenza vaccine
n (%)†
Controls, n=12150 (18–90)†*78 (65)NA89 (82.4)
AIIRD diagnosis, n
All patients with AIIRD, n=68659 (19–88)475 (69.3)10 (0–68)542 (79.4)
RA, n=26364 (20–88)215 (81.75)10 (0–50)213 (82.88)
PsA, n=16555 (20–86)78 (47.56)8 (0–68)120 (74.07)
AxSpA, n=6849.5 (21–83)36 (52.94)10 (1–51)54 (80.6)
SLE, n=10146 (22–80)89 (88.12)14 (0–44)76 (77.55)
IIM, n=1964 (34–76)14 (73.68)2 (1–21)19 (100)
Vasculitis, n=70
 LVV, n=2170 (26–85)17 (80.95)2.5 (0–12)20 (95.24)
 AAV, n=2660.5 (26–85)14 (53.85)4 (0.75–28)22 (84.62)
Other vasculitis, n=2356 (19–77)12 (52.17)6 (0.5–35)18 (78.26)
  • *Data on disease duration were available for 683 patients with AIIRD (they were missing for two patients with PsA and one patient with SLE).

  • †Data on influenza vaccination were available for 781 participants: 673 AIIRD and 108 controls.

  • ‡p<0.0001.

  • AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; AIIRD, autoimmune inflammatory rheumatic diseases; AxSpA, axial spondyloarthritis; IIM, idiopathic inflammatory myositis; LVV, large vessel vasculitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.